Atea Pharmaceuticals, Inc. (AVIR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.94-1.07 (-2.33%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 46.01 |
| Open | 46.02 |
| Bid | 44.00 x 900 |
| Ask | 46.05 x 800 |
| Day's Range | 43.83 - 46.42 |
| 52 Week Range | 24.15 - 94.17 |
| Volume | 433,911 |
| Avg. Volume | 329,793 |
| Market Cap | 3.718B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 82.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Zacks
Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?
Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- Zacks
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
- Simply Wall St.
Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders will have a reason to smile today, with the analysts making...
© 2021 Verizon Media. All rights reserved.
